Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2015

Collaboration Agreements

Schedule of Collaboration Agreements

Summarized financial information related to our collaboration agreements is presented below:

		Year ended December 31,										As of December 31,1
		Research and Development Expense
		Upfront Fees		Milestones		Extension/ Termination of Agreements		Amortization of Prepaid Research and Development		Equity Investments Made DuringPeriod		Intangible Asset Balance		Equity Investment Balance		Percentage of Outstanding Equity
Acceleron	2015	$	—	$	—	$	—	$	—	$	—	$	—	$	224.9	14	%
	2014	—		—		—		—		52.4		—		179.7		14	%
	2013	—		17.0		—		—		10.0
	2012 and prior	70.0		27.5		—		—		30.5
Acetylon	2015	—		—		—		20.2		15.0		0.2		30.0		14	%
	2014	—		—		—		15.3		—		20.4		25.0		10	%
	2013	50.0		—		—		4.3		10.0
	2012 and prior	—		—		—		—		15.0
Agios	2015	9.0		—		—		—		—		1.0		340.4		13	%
	2014	—		—		20.0		—		38.3		—		587.4		14	%
	2013	—		—		20.0		—		12.8
	2012 and prior	121.2		—		20.0		—		37.5
AstraZeneca	2015	450.0		—		—		—		—		—		N/A		N/A
bluebird	2015	—		—		—		4.9		—		20.2		N/A		N/A
	2014	—		—		—		0.1		—		0.1		N/A		N/A
	2013	74.7		—		—		—		—
Epizyme	2015	—		—		10.0		—		—		—		58.9		9	%
	2014	—		—		—		—		9.9		—		69.3		11	%
	2013	—		25.0		—		—		1.0
	2012	65.0		—		—		—		25.0
FORMA	2015	59.0		—		—		—		—		0.1		N/A		N/A
	2014	225.0		—		—		0.1		—		0.1		N/A		N/A
	2013	52.8		—		—		—		—
Juno	2015	575.1		—		—		—		424.9		—		401.8		9	%
Lycera	2015	87.0		—		—		—		10.0		3.0		10.0		8	%
NantBioScience2	2015	—		—		—		—		—		—		90.0		13	%
	2014	50.0		—		—		—		90.0		—		90.0		14	%
Nurix	2015	149.8		—		—		—		17.0		0.2		17.0		11	%
OncoMed	2015	2.5		70.0		—		—		—		—		33.1		5	%
	2014	2.5		—		—		—		—		—		32.0		5	%
	2013	155.0		—		—		—		22.2

		Year ended December 31,					As of December 31,1
		Research and Development Expense
		Upfront Fees	Milestones	Extension/ Termination of Agreements	Amortization of Prepaid Research and Development	Equity Investments Made During Period	Intangible Asset Balance	Equity Investment Balance	Percentage of Outstanding Equity
Sutro	2015	—	—	—	4.8	—	22.9	17.6	16	%
	2014	72.6	—	—	0.2	11.9	12.8	17.6	15	%
	2013	—	—	—	2.1	1.7
	2012	26.3	—	—	0.2	4.0
Other Collaboration Arrangements	2015	69.8	8.0	8.1	0.9	50.0	25.0	105.4	N/A
	2014	103.5	8.3	—	7.5	55.7	34.4	132.7	N/A
	2013	243.3	1.0	—	0.9	71.7

¹ Year-end balance and percentage of outstanding equity are presented for the current and prior year.

²$25.0 million of expense related to the settlement of contingent matching contributions was also recognized in 2014 at the inception of the collaboration agreement with NantBioScience and included in Selling, General and Administrative expense.